Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion type Assertion NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_head.
- NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion description "[Molecular analyses support the concept that there is a biological continuum between BL and DLBCL that includes variable activity of MYC, an oncoprotein once thought to be only associated with BL, but now recognized as a major predictor of survival among patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_provenance.
- NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion evidence source_evidence_literature NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_provenance.
- NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion SIO_000772 25468432 NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_provenance.
- NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion wasDerivedFrom befree-2016 NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_provenance.
- NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_assertion wasGeneratedBy ECO_0000203 NP1244266.RAfccz8hp51G-Mg9GsCPkTlXrI5LQu6OGZ-63Jy5unPX8130_provenance.